cessively with n-hexane, CH 2 Cl 2 , EtOAc and n-butanol, to give n-hexane (46.5 g), CH 2 Cl 2 (6.5 g), EtOAc (31.3 g) and n-butanol (31.8 g) soluble fractions, respectively. A portion of the EtOAc fraction (25.3 g) was subjected to silica gel column chromatography eluted with CH 2 Cl 2 : methanol (100 : 0→70 : 10, gradient) to yield nine fractions (E1-E9). Fraction E1 was rechromatographed on a silica gel column eluted with n-hexane : EtOAc (5 : 1→4 : 1) to give three subfractions (E1.1-E1.3). E1.2 was subjected to Sephadex LH-20 column chromatography eluted with methanol to yield pectolinarigenin ( Fig. 1) . Fraction E8 was recrystallized with methanol to give pectolinarin. The chemical structures of pectolinarigenin and pectolinarin were verified by comparison of the NMR data with those reported in the literature. 12, 13) Pectolinarigenin:
1 H-NMR (DMSO-d 6 , 300 MHz) d: 3.74, 3.84 (3H each, s, OCH 3 ), 6 .59 (1H, s, H-8), 6 .83 (1H, s, H-3), 7.08 (2H, d, Jϭ9.0 Hz, H-3Ј, 5Ј), 7.99 (2H, d, Jϭ9.0 Hz, H-2Ј, 6Ј), 13 .01 (1H, s, 5-OH). 9 Hz, H-3Ј, 5Ј), 6 .94 (1H, s, H-8), 6 .90 (1H, s, H-3), 5.12 (1H, d, Jϭ6.9 Hz, anomeric H of glucose), 4.58 (1H, s, anomeric H of rhamnose), 3 .87 (3H, s, OCH 3 ), 3 .78 (3H, s, OCH 3 ). 13 C-NMR (DMSO-d 6 , 75.5 MHz) d: 164.0 (C-2), 103.3 (C-3), 182.2 (C-4), 152.1 (C-5), 132.7 (C-6), 156.4 (C-7), 94.3 (C-8), 152.4 (C-9), 105.8 (C-10), 122.7 (C-1Ј), 128.3 (C-2Ј), 114.7 (C-3Ј), 162.3 (C-4Ј), 114.7 (C-5Ј), 128.3 (C-6Ј), 60.2 (6-OCH 3 ), 55.4 (4Ј-OCH 3 ), 100.3 (glu-1Љ), 73.1 (glu-2Љ), 76.4 (glu-3Љ), 69.5 (glu-4Љ), 75.7 (glu-5Љ), 65.9 (glu-6Љ), 100.4 (rha-1ٞ), 70.3 (rha-2ٞ), 70.7 (rha-3ٞ), 71.9 (rha-4ٞ), 68.2 (rha-5ٞ), 17.6 (rha-6ٞ).
RAW 264.7 Cell Culture and Measurement of PGE 2 Concentrations RAW 264.7 cells obtained from the American Type Culture Collection (ATCC, Rockville, MD, U.S.A.) were cultured in DMEM supplemented with 10% FBS and 1% antibiotics under 5% CO 2 at 37°C based on previously described procedures. 14) Briefly, cells were plated in 96-well plates (2ϫ10 5 cells/well). After pre-incubation for 2 h, the test compounds and LPS (1 mg/ml) were added and incubated for 24 h unless otherwise specified. Cell viability was assessed by the MTT assay as described previously. 15) From the media, PGE 2 concentration was measured using an ELISA kit for PGE 2 (Cayman Chem.) according to the manufacturer's instructions. To measure direct inhibition of COX-2, the cells were incubated with LPS (1 mg/ml) for 24 h. After the cells had been completely washed with serum-free DMEM, the test compounds and AA (100 mM) were added to COX-2-preinduced RAW 264.7 cells. Fifteen minutes later, PGE 2 concentration was measured in the media.
5-LOX Assay
In order to evaluate the inhibitory activity against 5-LOX, rat basophilic leukemia cells (RBL-1) purchased from ATCC were cultured in RPMI 1640 with 10% FBS, 2 mM glutamine and 1% antibiotics under 5% CO 2 at 37°C. The cells were plated in 96-well plates for 2 h. The test compounds were added and preincubated for 10 min. To activate 5-LOX, A-23187 (3 mM) was added and the cells were incubated for 15 min with a slight modification of the previously described procedure. 16) Media was collected and the concentration of the 5-LOX products, cysteinyl leukotrienes (LTC 4 /D 4 /E 4 ), was measured using an ELISA kit (Cayman Chem.) as recommended by the manufacturer.
Western Blot and Electrophoretic Mobility Shift Assay (EMSA) Western blotting was used to measure COX-2 expression.
14) RAW cells were cultured in 6-well plates (5ϫ10 6 cells/well) in the presence or absence of LPS (1 mg/ml) with/without test compounds for 20 h. After preparing cell homogenate, the supernatant was obtained by centrifugation at 15000 g for 30 min. Proteins were electrophoresed in Trisglycine gels (8%) and bands were blotted to PVDF membranes. The membranes were incubated with COX-2 antibody (No-160116, Cayman Chem.) and the bands were visualized by ECL-plus reagent (Amersham, Buckinghamshire, U.K.) and subsequent exposure to X-ray film. For EMSA analysis, RAW cells were treated with LPS and various concentrations of test compounds for 3 h. To prepare nuclear fractions, the cells were washed with PBS, harvested and resuspended in 400 ml of buffer A (10 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, pH 7.9) for 15 min on ice. After 10% NP-40 (25 ml) was added, the tubes were vortexed vigorously for 10 s. The nuclei were collected by centrifugation at 5000 rpm for 3 min and the supernatant was saved as the cytosolic fraction. The nuclei were lysed in buffer B (20 mM HEPES, 0.4 M NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, pH 7.9). The nuclear transcription factorkB (NF-kB) consensus oligonucleotide (Promega, Madison, WI, U.S.A.) was phosphorylated by T4 polynucleotide kinase (10 units) with 10 mCi of [g-32 P] ATP (3000 Ci/mmol) at 37°C for 10 min. Unincorporated oligonucleotides were removed by Microspin G-25 column (Amersham). Nuclear extract containing 5 mg protein was incubated with 32 P-labeled NF-kB consensus oligonucleotide in gel shift binding buffer at room temperature for 20 min. The incubation mixture was subjected to electrophoresis on a 4% polyacrylamide gel in TBE buffer (0.5ϫ) at 350 V. The gel was dried and exposed to X-ray film overnight at Ϫ70°C.
In Vivo Studies The experimental designs using animals were approved by the Committee for Animal Experimentation of the College of Pharmacy, Kangwon National University (CN-2008/19). The ethical guidelines described in the KFDA Guide for Care and Use of Laboratory Animals were followed throughout the experiments.
Arachidonic Acid-Induced Ear Edema in Mice: In order to evaluate the inhibitory activity of pectolinarigenin and pectolinarin in an animal model of acute inflammation, mouse arachidonic acid-induced ear edema was employed as previously described. 17) Briefly, 2% arachidonic acid in acetone was topically applied to ears of mice (20 ml/ear). One hour later, ear thickness was measured using a dial thickness gauge (Mitutoyo, Japan). Test compounds dissolved in DMSO (0.05 ml/mouse) were administered orally 1 h prior to arachidonic acid treatment.
l-Carrageenan (CGN)-Induced Paw Edema in Mice: To further establish the anti-inflammatory activity of the test compounds against acute inflammation, the mouse CGN-induced paw edema assay was also used with slight modification from the original procedures. 18) Test compounds were administered orally to mice. One hour later, 1% CGN (w/v) dissolved in pyrogen-free sterile saline solution (0.05 ml/ paw) was injected in the right hind paw; after 5 h, paw volume was measured using a plenthysmometer (Ugo Basil, Italy). The increase in paw volume from the initial nontreated paw volume was regarded as edema.
Passive Cutaneous Anaphylaxis (PCA) in Rats: To examine anti-allergic activity, the backs of the rats were shaved and injected intradermally with monoclonal anti-dinitrophenyl (DNP) mouse IgE (100 ml/site, 1 : 1000 dilution). After 48 h, PCA was induced by intravenous injection of the antigen (1 mg of DNP-bovine serum albumin) in PBS containing 1% Evans blue. Test compounds were orally administered twice 1 h prior to each IgE and antigen injection. Thirty minutes after antigen challenge, the skin was removed. Dye that leaked into the skin was extracted and quantified as previously described. 19) Statistical Analysis Experimental values were represented as arithmetic meanϮS.D. One-way ANOVA followed by Dunnett's test was used to determine the statistical significance. 2 and LT Production Treatment of the mouse macrophage-like cell line, RAW 264.7, with LPS (1 mg/ml) for 24 h induces COX-2, producing large amounts of PGE 2 . Also, upon activation with A23187 (calcium ionophore), RBL-1 cells produce great amounts of cysteinylLTs via 5-LOX. For example, in our experiments, the concentrations of PGE 2 and LTC 4 /D 4 /E 4 increased to 18.8Ϯ 2.3 nM and 1872.2Ϯ50.3 pg/ml from the control levels of 1.3Ϯ0.2 nM and 51.2Ϯ17.7 pg/ml, respectively. Under these conditions, we examined the methanol extract of C. chanroenicum and its solvent fractions for their inhibitory activities. Among the samples tested, the methanol extract and the ethylacetate fraction considerably inhibited PGE 2 and LT production ( Table 1) . Based on these results, the ethylacetate fraction was selected for further isolation of the active principle(s).
RESULTS

Inhibition of PGE
Through activity-guided isolation from the ethylacetate fraction using column purification, pectolinarigenin was successfully isolated, along with pectolinarin. Table 2 shows that pectolinarigenin significantly inhibited COX-2-mediated PGE 2 and 5-LOX-mediated LT synthesis at Ͼ1 mM, whereas pectolinarin exhibited no inhibitory activity at concentrations up to 50 mM. As expected, the reference compounds, NS-398 (selective COX-2 inhibitor) and NDGA (LOX inhibitor), potently inhibited COX-2 and 5-LOX, respectively. No significant cytotoxicity was observed in any groups tested in these experiments as measured by MTT assay (data not shown). To elucidate the mechanism of inhibition of PGE 2 production by pectolinarigenin, COX-2 expression was examined by Western blotting and the effect on NF-kB activation was measured by EMSA analysis. As shown in Fig. 2 , pectolinarigenin did not affect COX-2 expression or NF-kB activation, clearly indicating that the inhibition of COX-2-mediated PGE 2 production was not due to COX-2 down-regulation. On the other hand, pectolinarigenin did significantly inhibit PGE 2 production from COX-2-preinduced RAW cells (44.8% inhibition at 50 mM), while NS-398 showed 73.8% inhibition at 0.1 mM. These results suggest that pectolinarigenin may directly inhibit COX-2 enzymatic activity. Therefore, pectolinarigenin is likely a dual inhibitor of COX-2/5-LOX.
In Vivo Anti-inflammatory Activity To establish the in vivo anti-inflammatory activities of these compounds, pectolinarigenin and pectolinarin were tested in COX-2/5-LOX inhibitor-sensitive animal models of inflammation/allergy: arachidonic acid-induced ear edema, CGN-induced paw edema, and passive cutaneous anaphylaxis. Table 3 lists the in vivo anti-inflammatory activities of pectolinarigenin and pectolinarin. By oral administration, both significantly inhib- ited AA-induced mouse ear edema, but were less active against CGN-induced paw edema. In addition, these two compounds clearly inhibited allergic response (type I hypersensitivity) with similar inhibitory potencies (Table 4) .
DISCUSSION
The present investigation clearly demonstrates that pectolinarigenin and pectolinarin exhibit anti-inflammatory activity with similar potencies in animal models of inflammation and allergy, but are less potent than the reference drugs, indomethacin and prednisolone. The cellular mechanism of anti-inflammatory action of pectolinarigenin was, at least in part, due to COX-2/5-LOX inhibition that did not affect COX-2 expression. However, pectolinarin, a glycoside derivative of pectolinarigenin, did not inhibit COX-2/5-LOX in cell culture experiments, although it did show in vivo anti-inflammatory activity. Similar findings were previously reported. For example, flavonoid aglycones strongly inhibited lymphocyte proliferation and iNOS-catalyzed NO production in cell cultures, while their glycosides generally showed much less or no inhibition. 20, 21) However, oral administration of flavonoid glycosides sometimes gave similar or even higher in vivo activity compared to the corresponding flavonoid aglycones. 22) This phenomenon may be caused by the inaccessibility of flavonoid glycosides to the inside of the cell due to their hydrophilicity. On the other hand, orally administered flavonoid glycosides may enter the circulation through the intestinal wall, probably after hydrolysis of their glycosidic portion. 23, 24) The corresponding flavonoid aglycones and their methylated derivatives were found in the bloodstream, exerting in vivo pharmacological activity. Therefore, orally administered pectolinarigenin and pectolinarin may enter the bloodstream in the aglycone form (pectolinarigenin) and/or its related derivatives, thus showing similar potencies for anti-inflammatory activity in vivo.
Many flavonoid derivatives have previously been shown to possess anti-inflammatory activity in vitro as well as in vivo. 25, 26) Their anti-inflammatory cellular mechanisms include inhibition of eicosanoid metabolizing enzymes such as phospholipase A 2 , COXs and LOXs. In particular, flavonoids with a 5,7-dihydroxyl substitution and C-6 hydroxyl/ methoxyl group possess 5-LOX inhibitory activity. For instance, baicalein (5,6,7-trihydroxyflavone) was previously reported to inhibit 5-LOX activity.
27) Some C-5,6,7-substituted flavones that have an alkoxy group at C-5 or C-6 also inhibited 5-LOX. These synthetic flavones with an alkoxy group with 5-10 carbons had higher 5-LOX inhibitory activity. 28) The structurally similar flavone, nepetin (3Ј,4Ј,5,7-tetrahydroxy-6-methoxyflavone), inhibited COX and LOX. 29) In accordance with these reports, pectolinarigenin, which has a C-6 methoxyl group, inhibits 5-LOX. All of these findings suggest the importance of C-6 substitution with a hydroxyl/ methoxyl group for anti-inflammatory action.
While pectolinarigenin did not affect COX-2 expression, the structurally-related flavones, oroxylin A (5,7-dihydroxy-6-methoxyflavone) and wogonin (5,7-dihydroxy-8-methoxyflavone), were previously reported to down-regulate COX-2 and iNOS from the activated macrophages. 14, 30) Thus, it is suggested that B-ring substitution in pectolinarigenin may abolish the down-regulating capacity. All compounds dissolved in DMSO were administered orally. Negative control group without AA and CGN treatment showed 0.008Ϯ0.001 mm and 0.013Ϯ0.008 ml, respectively. a) nϭ6 (arithmetic meanϮS.D.). b) Values in parenthesis represent % inhibition compared to the AA-treated and CGN-treated control groups, respectively. * pϽ0.05, significantly different from the AA-treated and CGN-treated control groups, respectively. NT: not tested. It is well known that COX/LOX inhibitors inhibit AAinduced ear edema and CGN-induced paw edema, while 5-LOX inhibitors and steroidal anti-inflammatory drugs such as prednisolone are active against PCA. 31, 32) Pectolinarigenin and pectolinarin exhibited considerable inhibitory activity against these animal models, suggesting that they may also behave as COX/LOX inhibitors in vivo.
In this study, pectolinarigenin and pectolinarin were successfully isolated as the active anti-inflammatory principles from the aerial parts of C. chanroenicum. Pectolinarigenin and pectolinarin were also found to be the constituents of other Compositae family members 33) ; isolated from C. japonicum DC they inhibited tumor formation in mice. 34) Pectolinarin was previously found to possess in vivo anti-inflammatory and analgesic activities. 35) Recently, pectolinarigenin and pectolinarin isolated from C. setidens were demonstrated to reduce galactosamine-induced hepatic injury in rats. 36) To date, however, no study concerning the anti-inflammatory action of C. chanroenicum and pectolinarigenin has been described. This is the first report to describe phytochemical and pharmacological activity of C. chanroenicum, and to demonstrate anti-inflammatory activity and possible cellular mechanisms of pectolinarigenin.
In conclusion, pectolinarigenin and pectolinarin were successfully isolated from the aerial parts of C. chanroenicum. Pectolinarigenin strongly inhibited COX-2-mediated PGE 2 synthesis and 5-LOX-catalyzed LT production from LPStreated RAW 264.7 cells, leading to reduced eicosanoid production. In addition, oral administration of pectolinarigenin and pectolinarin inhibited animal models of inflammation and allergy. Therefore, these constituents may contribute to the anti-inflammatory action of C. chanroenicum at least in part by inhibiting eicosanoid synthesis. They also have potential as new anti-inflammatory/anti-allergic agents since COX inhibitors are used as anti-inflammatory agents and 5-LOX inhibitors show anti-allergic activity.
